Podnosis Fierce Healthcare

Earlier this year, Fierce Healthcare, Fierce Pharma and Fierce Biotech recognized 50 individuals and companies that are pushing the industry forward. The Fierce 50 winners range from tech innovators to researchers developing novel therapies to providers on the frontlines of changing care. This week on Podnosis, senior editor Paige Minemyer sat down with staff writers Dave Muoio and Anastassia Gliadkovskaya as well as senior editor Heather Landi to discuss a few of the honorees in more detail. 

To learn more about the topics in this episode: 

The Fierce 50 of 2023 
See omnystudio.com/listener for privacy information.

Chronic kidney disease is a significant public health issue. Nationwide, roughly 37 million Americans live with chronic kidney disease. Each year, more than 130,000 Americans receive a diagnosis of kidney failure or end-stage renal disease, an irreversible condition that can be fatal.

DaVita is one of the largest providers of kidney care, and its services range from slowing the progression of kidney disease to supporting transplantation. This week on "Podnosis," Senior Editor Heather Landi sits down with Misha Palecek, who leads DaVita’s strategic value-based care partnerships and care delivery innovations, to discuss why the shift to value-based care is critical in raising the bar on kidney care and addressing widespread healthcare disparities.

To learn more about the topics in this episode: 



More than half of Americans are unfamiliar with chronic kidney disease, survey finds


DaVita, Medtronic raise the curtain on tech company, Mozarc Medical, aiming to bring innovation to kidney care

Program promises to take a team approach to tackling severe kidney disease



DaVita CEO Javier Rodriguez talks integrated kidney care, competitive threats and regulation



Home care industry touts bipartisan bill to expand Medicare in-home benefits, reimbursement



 
See omnystudio.com/listener for privacy information.

In this week’s episode of "Podnosis," you'll hear from two journalists from the Fierce Healthcare team: Paige Minemyer, senior editor of Fierce Health Payer, and Dave Muoio, a staff writer for Fierce Healthcare. Together, they guide you through their key insights from the inaugural Fierce Health Payer Summit in Austin and dive into the latest earnings updates from the largest health plans and health systems.

To learn more about the topics in this episode: 


UnitedHealth sees a 'mixed bag' of responses to GLP-1 demand
CVS Health beats the Street with $2.3B in Q3 profit
Sutter Health slips to 0.1% operating margin, $98M net loss in Q3
Kaiser Permanente logs $239M net income, 0.6% operating margin in Q3 2023
Cigna boosts guidance as it posts $1.4B in profit for Q3
Humana raises MA enrollment projections again, beats EPS market estimates
Community Health Systems brings more physicians in-house to combat high labor costs, staffing fees
UHS beats with $167M Q3 profit, but has more work securing payments, reducing physician expenses on its plate
HCA Healthcare's newly consolidated physician staffing venture is bleeding $50M per quarter, execs tell investors
Centene still expects to lose more than 2M members as Medicaid redeterminations reach midway point
Elevance Health braces for $500M hit to bonus revenue amid MA star ratings drop
See omnystudio.com/listener for privacy information.

Hello Heart, a digital platform designed to help people manage their heart health, is a U.S.-based company with offices in California and New York, and it also has a significant presence in Israel, with the majority of its roughly 80 employees there working from the Tel Aviv office.  

In this week’s episode of “Podnosis,” Hello Heart CEO Maayan Cohen, who resides in Tel Aviv, shares her personal experience during a challenging moment when she was on her way to the annual HLTH conference in Las Vegas and heard about the October 7th attack by Hamas on Israel. At that moment, Cohen was unable to help get her employees, some of whom were in the strike zone, to safety. She sat down with Fierce’s Anastassia Gliadkovskaya to talk about what she did next and her strategy for leading Hello Heart through the crisis. 
See omnystudio.com/listener for privacy information.

In this week's episode of “Podnosis,” we explore Blue Shield of California's plan to transform its pharmacy model. This includes a shift away from the traditional PBM relationship in favor of forming partnerships with five companies: Amazon Pharmacy, Abarca, Mark Cuban Cost Plus Drugs Company, CVS Caremark and Prime Therapeutics. 

Fierce's Paige Minemyer sat down with Blue Shield of California's Chief Operating Officer, Sandra Clarke, to discuss the new approach to pharmacy benefits. 

To learn more about the topics in this episode: 


PBMs under fire again as Senate introduces new bill
Blue Shield of California ditches CVS Caremark as PBM, unveils new pharmacy care model
Blue Shield of California bringing Wellvolution program to Medi-Cal plans
See omnystudio.com/listener for privacy information.

In this week's episode of “Podnosis,” we look at the major health disparities facing Native Americans and explore what can be done to make meaningful improvements. 

Misty Wilkie, Ph.D., RN, a clinical associate professor at the University of Minnesota School of Nursing, has a deep understanding of the challenges in obtaining high-quality care, drawing from her own experiences as an American Indian. In a conversation with Anastassia Gliadkovskaya from Fierce, she shares her efforts to enhance diversity and cultural competency within the healthcare system. 

To learn more about the topics in this episode: 



2 in 5 Native Americans visit ER due to diabetes complications, survey finds



Systemic racism, nonstandard data collection hamper hospital equity officers' efforts, survey shows



Maternal death rates nearly doubled in 2 decades, study finds. Inconsistent data collection also hampers improvement efforts



Commonwealth Fund gives healthcare in southeastern states failing grades across the board


See omnystudio.com/listener for privacy information.